Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%
The study showed statistically significant and clinically meaningful survival results.
The data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the New England Journal of Medicine.In a second interim analysis of overall survival (OS), a key secondary endpoint, the BRAFTOVI combination regimen reduced the risk of death by 51% compared to standard-of-care chemotherapy with or without bevacizumab (Hazard Ratio [HR] 0.49).
Median OS was 30.3 months with BRAFTOVI in combination with cetuximab and mFOLFOX6 compared to 15.1 months with chemotherapy with or without bevacizumab.
In the primary analysis of progression-free survival (PFS), the BRAFTOVI combination regimen reduced the risk of disease progression or death by 47% compared to standard-of-care chemotherapy with or without bevacizumab (HR 0.53) as assessed by blinded independent central review (BICR).
Median PFS was 12.8 months with the BRAFTOVI combination regimen compared to 7.1 months.
The updated objective response rate (ORR) by BICR confirmed the improvement previously observed with the BRAFTOVI combination regimen compared to patients receiving chemotherapy with or without bevacizumab.
The prior primary analysis also maintained the estimated median duration of response and median time to response.
The BRAFTOVI combination regimen received accelerated approval by the U.S. Food and Drug Administration (FDA) in December 2024 for patients with BRAF V600E -mutant mCRC based on a clinically meaningful and statistically significant improvement in confirmed ORR in treatment-naïve patients, the study's other dual primary endpoint.
Continued approval for this indication is contingent upon verification of clinical benefit.
The BREAKWATER survival data are being discussed with the U.S. FDA to support potential conversion to full approval in 2025.
Price Action: PFE stock is up 0.51% at $23.57 at the last check on Friday.
Read Next:Photo via Shutterstock
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
PFIZER (PFE): Free Stock Analysis Report
This article Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50% originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
登入存取你的投資組合
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 minutes ago
- Business Wire
EQUITY ALERT: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE: DHR). If you currently own shares of Danaher stock, please visit the firm's website at for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@ Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for a number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
Business Wire
7 minutes ago
- Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SelectQuote
NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against SelectQuote, Inc. ('SelectQuote' or the 'Company') (NYSE:SLQT) and reminds investors of the October 10, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements Share Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that the Company was directing Medicare beneficiaries to the plans offered by insurers that best compensated SelectQuote, regardless of the quality or suitability of the insurers' plans; (2) that SelectQuote did not provided unbiased comparison shopping for Medicare Advantage insurance plans; (3) that SelectQuote received illegal kickbacks to steer Medicare beneficiaries to certain insurers and limit enrollment in competitors' plans; (4) that as a result, SelectQuote had not complied with applicable laws, regulations, and contractual provisions; (5) that SelectQuote was vulnerable to regulatory and legal sanctions as a result of its conduct, including claims that it had violated the False Claims Act; and (6) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On May 1, 2025, the U.S. Department of Justice ('DOJ') filed a False Claims Act complaint against SelectQuote, alleging, '[f]rom 2016 through at least 2021' SelectQuote received 'tens of millions of dollars' in 'illegal kickbacks' from health insurance companies in exchange for steering Medicare beneficiaries to enroll in the insurers' plans. Further, SelectQuote, in exchange for kickbacks, engaged in a conspiracy with major insurers to illegally discriminate against beneficiaries deemed to be less profitable, including those with disabilities. The DOJ concluded that SelectQuote made materially false claims by stating it offers 'unbiased coverage comparisons' when in fact it 'repeatedly directed Medicare beneficiaries to the plans offered by insurers that paid them the most money, regardless of the quality or suitability of the insurers' plans.' On this news, SelectQuote's stock price fell $0.61, or 19.2%, to close at $2.56 per share on May 1, 2025, on unusually heavy trading volume. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding SelectQuote's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the SelectQuote class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Yahoo
43 minutes ago
- Yahoo
If You'd Invested $1,000 in Berkshire Hathaway Stock 5 Years Ago, Here's How Much You'd Have Today
Key Points Like all funds and portfolios, Berkshire Hathaway has underperformed from time to time. Warren Buffett's quality-oriented approach to buying and holding stocks has paid off of late. 10 stocks we like better than Berkshire Hathaway › Artificial-intelligence-related tech stocks like Nvidia and Palantir have dominated headlines and led the marketwide bullish charge over the past five years. But, not every market-beating stock has been an AI technology name -- or even a growth name -- during this stretch. Warren Buffett and his team have proven their mettle once again, leading value-oriented Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) to a market-beating performance of its own since the middle of 2020. Back in fighting form If you had you invested $1,000 in Berkshire Hathaway shares in early August of 2020, as I write this on Aug. 10, you'd be sitting on $2,221. That's an annualized growth rate of 17.3%, outpacing the S&P 500 's (SNPINDEX: ^GSPC) average annual growth pace of 13.8%, or 15.5% when factoring in reinvested dividends. Making this five-year run even more impressive is that Berkshire has performed relatively poorly since May. That's not only when Buffett announced his end-of-year retirement, but also when investors began shedding their defensive value stocks that Buffett's conglomerate holds so they could plow back into growth-oriented technology names. It's still well ahead despite the headwind. There's also some vindication in this market-beating performance. You may recall that Berkshire's persistent underperformance for several years prior to 2021's rekindled leadership was prompting criticisms and questions of his old-school stock-picking approach. The past three years have reminded everyone that patience pays off when you prioritize owning quality businesses rather than chasing growth. Buying and holding quality is always a sound strategy Don't misunderstand. Just as it did for several years prior to 2021, there will come another time when Berkshire Hathaway shares lag the market. That's just the nature of Warren Buffett's value-minded style -- it tends to underperform when investors are captivated by new, game-changing industries. Just remember the past five years the next time that happens, and the past three years in particular. A truly great stock is worth buying and holding even through the rough patches. Should you buy stock in Berkshire Hathaway right now? Before you buy stock in Berkshire Hathaway, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Berkshire Hathaway wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway, Nvidia, and Palantir Technologies. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Berkshire Hathaway Stock 5 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool Sign in to access your portfolio
